Given that many heart failure patients already receive β1-AR blocker therapy, our findings raise the possibility that a short course of low-dose parenteral T3 therapy, which is also a clinically approved drug, might be sufficient to regenerate postischemic hearts with severe progressive heart failure. Here, ADRB1 is linked to heart failure.